Cargando…
HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
OBJECTIVES: We report a case of incomplete HIV-1 suppression on a dolutegravir, lamivudine, and abacavir single-tablet regimen with the emergence of the H51Y and G118R integrase resistance mutations. METHODS: Integrase sequencing was performed retrospectively by Sanger and next-generation sequencing...
Autores principales: | van Kampen, Jeroen J.A., Pham, Hanh Thi, Yoo, Sunbin, Overmars, Ronald J., Lungu, Cynthia, Mahmud, Rizwan, Schurink, Carolina A.M., van Boheemen, Sander, Gruters, Rob A., Fraaij, Pieter L.A., Burger, David M., Voermans, Jolanda J.C., Rokx, Casper, van de Vijver, David A.M.C., Mesplède, Thibault |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258191/ https://www.ncbi.nlm.nih.gov/pubmed/36347497 http://dx.doi.org/10.1016/j.jgar.2022.11.001 |
Ejemplares similares
-
Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA
por: Lungu, Cynthia, et al.
Publicado: (2020) -
Erratic enteric absorption of dolutegravir in a critically ill patient
por: de Antonio-Cuscó, Marta, et al.
Publicado: (2022) -
Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors
por: Lungu, Cynthia, et al.
Publicado: (2023) -
Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018) -
Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)